IP Strategy · Building Value
Building a Patent Portfolio
A patent portfolio is a collection of patents and applications managed as a strategic business asset. The most valuable portfolios are purpose-built — not accidental accumulations of whatever the patent attorney filed.
Key takeaways
- →Quality over quantity — one broad independent claim covering a core invention is worth more than 50 narrow patents on peripheral features.
- →File early, file often — continuation applications let you pursue new claims from the same disclosure as your product evolves.
- →Build the family, not just the patent — US + EP + CN coverage is the modern minimum for a market-facing technology company.
- →Align filing strategy with business: offensive (licensing/assertion), defensive (deterrence/cross-licensing), or both.
- →Maintenance is strategic — regularly audit and deliberately lapse patents that are no longer business-relevant.
- →Own your IP — ensure all employment agreements, contractor agreements, and assignment documents are recorded at the USPTO.
Portfolio purpose
Three portfolio strategies
Most companies use a mix, but understanding the primary purpose of your portfolio determines what to file, how broadly to draft claims, and how much to spend on geographic coverage.
Offensive
Filing patents to generate licensing revenue, to assert against competitors infringing your space, or to create leverage in negotiations. Offensive patents must have broad, well-drafted claims and clear chain of title.
Examples
- Licensing royalty streams
- Assertion against copycat competitors
- Cross-licensing leverage with large incumbents
Typical for
Patent assertion entities (PAEs), established technology companies, pharma/biotech
Defensive
Filing patents to deter suits from competitors and to have assets to cross-license. A company without patents can be sued freely — a company with a portfolio creates the threat of counter-assertion. Most early-stage startup patents are primarily defensive.
Examples
- Deterrence (mutual assured destruction)
- Cross-license building blocks
- Prior art creation (defensive publication)
Typical for
Technology startups, software companies, any company that builds products for sale
Licensing
Licensing patents to third parties for royalty income, either as the primary business model or as a secondary revenue stream. Requires broad, enforceable claims, proven willingness to litigate, and a portfolio large enough to be worth licensing.
Examples
- Licensing programs (Qualcomm, ARM, IBM)
- University tech transfer
- Patent pools (MPEG LA, Via Licensing)
Typical for
Universities, R&D-heavy companies, established technology companies
Building blocks
How a portfolio is built over time
Portfolios are not filed all at once — they grow through a combination of original applications, continuation families, design patents, and international filings. The most efficient approach:
Core filing
File a non-provisional (or provisional + conversion) on the central invention — the core technical innovation that gives your product its competitive advantage. Draft the broadest defensible independent claims, with multiple narrower fallback dependents. This is the anchor of the portfolio.
Continuation strategy
While the parent application is pending, file continuation applications targeting different claim formats (system claims, method claims, apparatus claims), different embodiments, and improvements observed in the market. Each continuation can claim a filing date as early as the original — making continuations one of the most powerful portfolio-building tools.
Design patents
File design patents on the distinctive visual elements of your product (UI layouts, hardware form factors, packaging). Design patents are inexpensive ($1,500–$5,000 total), quick (12–18 months to grant), and create legal risk for copycat competitors. Apple's billions in damages from Samsung relied heavily on design patents.
International coverage
File a PCT (Patent Cooperation Treaty) application within 12 months of the US priority date to preserve international patent rights in 150+ countries with a single filing. Then elect national phases at 30 months. Focus on: US (granted or pending), EP (European Patent for 38 countries in one prosecution), CN (China — critical for manufacturing and consumer markets), and JP (Japan — major technology market). KR (Korea) and IN (India) for relevant industries.
Portfolio maintenance and pruning
Conduct an annual patent audit. Deliberately lapse patents whose technology is obsolete, products are discontinued, or claims are too narrow to be useful. US maintenance fees at 3.5, 7.5, and 11.5 years are an annual review forcing function. Pruning reduces cost and focuses resources on patents that matter.
Investor diligence
What VCs and acquirers look at in IP due diligence
IP due diligence at Series A and beyond — and in any M&A transaction — examines whether the company’s patents protect what matters, whether ownership is clean, and whether there are lurking FTO risks.
Coverage
Do the patents protect the core technology, or only peripheral features? A patent on the product’s core mechanism is worth far more than one on an ancillary button placement.
Claim breadth
Are independent claims broad enough to capture obvious variations? Narrow claims can be designed around — they protect the exact embodiment but not the competitive space.
Ownership and assignment
Are all inventors identified? Are all inventor assignments recorded at the USPTO? Employment agreements with IP assignment clauses? Contract/consultant work-for-hire agreements? Gaps here can leave ownership ambiguous.
Status and prosecution health
Are patents granted, pending, or abandoned? Excessive RCEs may signal weak prosecution. Appeals or continuations pending? Are maintenance fees current?
Geographic coverage
Are key markets covered? A US-only patent doesn’t protect against Chinese or European competition. Was PCT filed timely to preserve international rights?
FTO for own product
Has the company done FTO analysis on its own product? Are there third-party patents that might require licensing before product launch?
No encumbrances
Are any patents pledged as collateral? Licensed to third parties? Subject to a government march-in right (Bayh-Dole)?
Common mistakes
What wastes IP budget
Filing too narrow
Claims drafted around the specific product rather than the broadest defensible invention. Competitors design around easily. Write claims around the inventive concept, not the product spec.
Missing the provisional window
Disclosing an invention (publication, demo, sale) without filing a provisional application first. In the US, the one-year grace period may save you — but in most countries, public disclosure before filing is fatal.
Forgetting continuation timing
Allowing a parent application to issue without filing continuation applications targeting additional claim formats or improvements. Once the parent issues, the continuation window for that disclosure closes.
No PCT application filed
Failing to file PCT within 12 months of the priority date. This forfeits international patent rights — you cannot get a European, Chinese, or Japanese patent on that disclosure without the PCT (or a direct foreign filing within 12 months).
Ownership gaps
Contractors, co-founders, and advisors who contributed to the invention may have rights. All contributors must sign assignment agreements. Unfixed ownership gaps discovered in diligence kill M&A deals.
Paying maintenance on dead weight
Paying maintenance fees on expired products, obsolete technology, or claims too narrow to use. Annual portfolio audits and deliberate lapsing of low-value patents save significant budget.
FAQ
Common patent portfolio questions
How many patents does a startup need?
There is no magic number. The right portfolio size depends on the industry, competitive landscape, and business objectives. For software startups, even 3–5 well-drafted patents covering core technical innovations can provide meaningful competitive protection and satisfy investor due diligence. For hardware, biotech, and pharmaceutical companies, significantly larger portfolios are common — pharma companies routinely build 100+ patent families around a single drug product (method of treatment, formulation, manufacturing process, dosing regimens). Quality matters more than quantity: a single broad patent covering a core invention is worth more than 50 narrow patents on peripheral features.
What do investors look for in a patent portfolio?
Investors conducting IP due diligence (especially at Series A and beyond) evaluate: (1) Coverage — do the patents protect the core technology that drives the business, or are they peripheral? (2) Claim breadth — are the claims broad enough to block competitors, or so narrow a competitor can easily design around? (3) Prosecution status — pending applications suggest ongoing coverage expansion; heavy RCE use may signal a weak prosecution. (4) Geographic coverage — are patents filed in the key markets (US, EU, China, Japan)? (5) Ownership — are all inventors listed and have all assignments been properly recorded at the USPTO? (6) Freedom to operate — does the company have FTO for its own product? A portfolio with strong claims, clear ownership, and FTO analysis is a diligence-ready asset.
What is a patent thicket?
A patent thicket is a dense web of overlapping patent rights that a new market entrant must navigate through — by licensing, designing around, or challenging. Large incumbents often deliberately build thickets around core technologies by filing hundreds of patents covering a product from multiple angles (the device, the manufacturing process, materials, methods of use, aesthetic design, interface, software). The smartphone industry, semiconductor manufacturing, and standard-essential patents (SEPs) are classic examples. For startups entering a thicketed space, FTO analysis is essential before committing to a product architecture.
What is a patent cross-license and why do large companies do them?
A cross-license is an agreement where two companies grant each other licenses to their respective patent portfolios — often royalty-free or at reduced rates. Large technology companies (IBM, Microsoft, Samsung, Intel, Qualcomm) frequently execute cross-licenses to create a 'peace treaty' that allows both companies to operate freely without ongoing infringement risk. Cross-licenses require that both parties have portfolios the other values — a startup with one patent cannot cross-license with IBM's 10,000-patent portfolio. This is one reason large companies build large portfolios: to have leverage in cross-license negotiations. Cross-licenses often also release past infringement claims.